Gut Bacteria Linked to High Blood Pressure and Depression
|
By LabMedica International staff writers Posted on 17 Sep 2019 |

Image: This infographic illustrates the connection between the brain, central nervous system and other organs and how they interact with a person\'s gut microbes to show different patterns from people with high blood pressure plus depression; high blood pressure without depression; depression with healthy blood pressure; or healthy subjects without depression or high blood pressure (Photo courtesy of Professor Bruce R. Stevens, PhD).
The microbiome is the genetic material of all the microbes, bacteria, fungi, protozoa and viruses that live on and inside the human body. The number of genes in all the microbes in one person's microbiome is 200 times the number of genes in the human genome.
A study of human gut bacteria, known as the gut microbiome, suggests that high blood pressure with depression may be a completely different disease than high blood pressure without depression. The gut may be targeted someday to prevent, diagnose and selectively treat different forms of high blood pressure with or without depression.
Scientists from the University of Florida College of Medicine (Gainesville, FL, USA) made a study of bacteria in the gut identified differences between people with high blood pressure compared to those with high blood pressure plus depression. They isolated DNA (deoxyribonucleic acid, the carrier of genetic information) from gut bacteria obtained from the stool samples of 105 volunteers. They used a new technique involving artificial-intelligence software to analyze the bacteria, which revealed four distinct types of bacterial genes and signature molecules.
Surprisingly, the investigators discovered unique patterns of bacteria from people with 1) high blood pressure plus depression; 2) high blood pressure without depression; 3) depression with healthy blood pressure; or 4) healthy subjects without depression or high blood pressure. The authors concluded that the results suggest different medical mechanisms of high blood pressure that correlate with signature molecules produced by gut bacteria. These molecules are thought to impact the cardiovascular system, metabolism, hormones and the nervous system.
Bruce R. Stevens, PhD, a Professor of Physiology & Functional Genomics, Medicine and Psychiatry and the lead author of the study, said, “People are 'meta-organisms' made up of roughly equal numbers of human cells and bacteria. Gut bacteria ecology interacts with our bodily physiology and brains, which may steer some people towards developing high blood pressure and depression. We believe we have uncovered new forms of high blood pressure: 'Depressive Hypertension' (high blood pressure with depression), which may be a completely different disease than 'Non-Depressive Hypertension' (high blood pressure without depression), which are each different from 'Non-Hypertensive Depression.” The study was presented at the American Heart Association's Hypertension 2019 Scientific Sessions on September 5, 2019, in New Orleans, LA, USA.
Related Links:
University of Florida College of Medicine
A study of human gut bacteria, known as the gut microbiome, suggests that high blood pressure with depression may be a completely different disease than high blood pressure without depression. The gut may be targeted someday to prevent, diagnose and selectively treat different forms of high blood pressure with or without depression.
Scientists from the University of Florida College of Medicine (Gainesville, FL, USA) made a study of bacteria in the gut identified differences between people with high blood pressure compared to those with high blood pressure plus depression. They isolated DNA (deoxyribonucleic acid, the carrier of genetic information) from gut bacteria obtained from the stool samples of 105 volunteers. They used a new technique involving artificial-intelligence software to analyze the bacteria, which revealed four distinct types of bacterial genes and signature molecules.
Surprisingly, the investigators discovered unique patterns of bacteria from people with 1) high blood pressure plus depression; 2) high blood pressure without depression; 3) depression with healthy blood pressure; or 4) healthy subjects without depression or high blood pressure. The authors concluded that the results suggest different medical mechanisms of high blood pressure that correlate with signature molecules produced by gut bacteria. These molecules are thought to impact the cardiovascular system, metabolism, hormones and the nervous system.
Bruce R. Stevens, PhD, a Professor of Physiology & Functional Genomics, Medicine and Psychiatry and the lead author of the study, said, “People are 'meta-organisms' made up of roughly equal numbers of human cells and bacteria. Gut bacteria ecology interacts with our bodily physiology and brains, which may steer some people towards developing high blood pressure and depression. We believe we have uncovered new forms of high blood pressure: 'Depressive Hypertension' (high blood pressure with depression), which may be a completely different disease than 'Non-Depressive Hypertension' (high blood pressure without depression), which are each different from 'Non-Hypertensive Depression.” The study was presented at the American Heart Association's Hypertension 2019 Scientific Sessions on September 5, 2019, in New Orleans, LA, USA.
Related Links:
University of Florida College of Medicine
Latest Pathology News
- Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
- AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
- AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
- AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
- AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
- Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
- Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
- AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
- Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
- Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
- New AI Model Maps Where Glioblastoma Could Return After Surgery
- Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
- Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
- Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
- Machine Learning Cytology Tool Improves Cancer Cell Identification
Channels
Clinical Chemistry
view channel
Common Kidney Function Tests May Miss CKD in Cancer Patients
Chronic kidney disease (CKD) can complicate cancer care, as reduced kidney filtration may affect treatment eligibility and dosing. In oncology, kidney function assessment often relies on estimated glomerular... Read more
Point-of-Care Blood Biomarker Test Detects Brain Injury Missed by CT
Traumatic brain injury remains difficult to assess in emergency settings because some patients continue to have symptoms despite normal computed tomography findings. Approximately 2.8 million people in the U.... Read moreMolecular Diagnostics
view channel
Updated Framework Guides Assessment of Actionable Cancer Biomarkers
Cancer care increasingly relies on molecular testing to guide targeted treatment selection. Broader use of tumor sequencing has expanded the volume and diversity of biomarker data available to oncologists,... Read more
Genomic Tissue Test Predicts Metastasis and Abiraterone Benefit in High-Risk Prostate Cancer
Prostate cancer is the most common cancer in men, affecting more than 1 million men worldwide in 2013. Its clinical course varies substantially between patients, complicating efforts to identify those... Read moreHematology
view channel
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read moreImmunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read morePathology
view channel
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
Compact PCR Thermal Cycler Launches for Routine Molecular Laboratory Workflows
Molecular laboratories rely on nucleic acid analysis to detect molecular information accurately and reproducibly across a wide range of applications. Supporting these routine workflows, a newly launched... Read more
New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read moreIndustry
view channel
Collaboration Brings Tumor-Informed MRD Monitoring to Breast Cancer Care in Abu Dhabi
For many patients, cancer treatment does not eliminate the risk of recurrence, which may occur months or years later and become harder to treat after spreading. Recurrence is often detected only after... Read more







